Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty

Breast Cancer Research

Table 3 Patient immune profiles correlating with clinical frailty in the whole population (the CTG and CG) prior to receiving systemic therapy at baseline

Geriatric measure	Phenotype	p Value, r value, number
LOFS	CD4+/CD57+	0.0178, r = 0.341, n = 48
LOFS	CD8+/CD27	0.0367, r = 0.302, n = 48
LOFS	CD4+/CD25hi FOXP3+	0.0407, r = 0.291, n = 50
LOFS	CD4+/FOXP3+	0.0002, r = 0.510, n = 50
LOFS	CD14-negative/CD15+/CD124+	0.0292, r = 0.303, n = 52
LOFS	CD14-negative/HLA-DR-negative/CD11b+	0.0195, r = 0.323, n = 52
LOFS	CD15+	0.0246, r = -0.311, n = 52
G8	CD4+/FOXP3+	0.0147, r = 0.340, n = 51
G8	CD14-ve/HLA-DR-negative/CD11b+	0.0403, r = 0.280, n = 54

Negative r values indicate inverse association and positive r values show positive correlation between patient geriatric status (“Geriatric measure”) and the indicated leukocyte population (“Phenotype”). Lower G8 and Leuven oncology frailty score (LOFS) values designate more frail patients and high values indicate fitter patients. CTG chemotherapy group, CG control group

ISSN: 1465-542X